mRNA vaccine targeting an outer surface protein provides protection against multiple Lyme disease strains

OspC mRNA vaccines protected mice against some Borrelia strains, but polyvalent strain coverage was incomplete.

Preclinical mouse vaccine-challenge study tested monovalent OspC type A and polyvalent OspC types A, C, I, K, and N mRNA vaccines against multiple Borrelia burgdorferi strains.

The polyvalent vaccine protected against OspC types A, I, and K but not C or N at the tested formulation, and all efficacy evidence was in mice.